Clarity Pharmaceuticals Ltd CU6
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- A$1.73
- Day Range
- A$1.72–1.79
- 52-Week Range
- A$1.72–5.32
- Bid/Ask
- A$1.75 / A$1.75
- Shares Outstanding
- 373.08M
- Market Cap
- A$654.76M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation products that improve treatment outcomes for people with cancer. Its products use the perfect pairing of copper isotopes, copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy, which deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers. Its core clinical-stage programs, SAR-bisPSMA, SARTATE and SAR-Bombesin, each contain a different targeting agent that binds to specific receptors that are present on different cancer cells. It operates as one segment Development of Radiopharmaceuticals in Australia and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
Valuation
|
Metric
|
CU6
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.66 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CU6
|
|---|---|
Quick Ratio | 15.49 |
Current Ratio | 16.09 |
Interest Coverage | — |
Quick Ratio
CU6
Profitability
|
Metric
|
CU6
|
|---|---|
Return on Assets (Normalized) | −57.82% |
Return on Equity (Normalized) | −63.13% |
Return on Invested Capital (Normalized) | −66.43% |
Return on Assets
CU6
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zbwS#^Y | LOCK|jLhG$ | $126B | |||
| Moderna Inc
MRNA
| LOCK|bMg@!^ | LOCK|!! | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|V>##XCz | LOCK|&^Vt | $80B | |||
| argenx SE ADR
ARGX
| LOCK|w&<LLn | LOCK|Ln | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|VF%VvM | LOCK|Dlb | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<$l>?m | LOCK|W^d> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|h>QBD^@n | LOCK|LbtY | $26B | |||
| Incyte Corp
INCY
| LOCK|>r?q?> | LOCK|!K@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|qrYCNfs | LOCK|R!b | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@r#B&sz | LOCK|%Jp | $14B |
United States